BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical ...

Retrieved on: 2024-12-21 02:04:00

Tags for this article:

Immunology

Antibody-drug conjugate

Prospectus

Bi-specific T-cell engager

AXL receptor tyrosine kinase

Bispecific monoclonal antibody

Monoclonal antibody therapy

Seagen

bioatla, inc.

Click the tags to see associated articles and topics

BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical .... View article details on hiswai:

Excerpt

20, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company (“BioAtla” or the “Company”) focused on the ...

Article found on: www.theglobeandmail.com

View Original Article